Menu TARGET A BETTER NOW Targeting a better life for people with cancer is why we get up in the morning. It’s not enough to disrupt the progress of someone’s cancer; we want to keep cancer from disrupting someone’s life. OUR SCIENCE Antibody-drug conjugates, or ADCs, are a targeted way to treat cancer. For 40 years, ImmunoGen has been researching and developing ADCs designed to disrupt the progression of cancer. Because we believe life deserves fewer interruptions and more good days. LEARN MORE 40 YEARS AGO, IMMUNOGEN BEGAN AS AN IDEA Baruj Benacerraf, head of the Sidney Farber Cancer Institute (now the Dana Farber Cancer Institute), was approached by a small group of investors with a vision: to create more effective, better tolerated anti-cancer therapies. Specifically, they wanted to find a way to leverage the targeting ability of antibodies to deliver toxic drug directly to cancer cells. Benacerraf went on to suggest that the investors start with a grant from which the Institute would work with dedicated scientists. The rest, they say, is our history… LEARN MORE LATEST NEWS Nov 30, 2021 ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer Read More Nov 17, 2021 ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors Read More Nov 16, 2021 ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer Read More CONTACT US PRIVACY POLICY USAGE POLICY © 2021 ImmunoGen, Inc., All Rights Reserved ImmunoGen, the ImmunoGen logos, and TARGET A BETTER NOW are trademarks or registered trademarks of ImmunoGen, Inc.